Immunoglobulin-like transcript 2 (ILT2) is a biomarker of therapeutic response to oncolytic immunotherapy with vaccinia viruses

Journal for ImmunoTherapy of Cancer

Howard L Kaufman⁵  Francesco M Marincola⁶  Vladia Monsurro¹  Michael C Jagoda⁴  Seunghee Kim-Schulze³  Dae Won Kim⁴  Andrew Zloza² 

[1] Department of Pathology and Diagnostic, University of Verona Medical School, Verona, Italy;Department of Immunology/Microbiology, Rush University Medical Center, 1750 West Harrison Street, Chicago, IL 60612, USA;The Tumor Immunology Laboratory, Department of Surgery, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029, USA;Rush University Cancer Center, 1725 West Harrison Street, Chicago, IL 60612, USA;Rutgers Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08903, USA;Research Branch, Sidra Medical and Research Centre, Doha, Qatar

关键词: Cancer vaccines;    T cells;    Immunotherapy;    Oncolytic virus;    Vaccinia;    Biomarker;    Immunoglobulin-like transcript 2;   

Others  :  814835
DOI  :  10.1186/2051-1426-2-1

 received in 2013-12-04, accepted in 2014-01-16,  发布年份 2014

【 摘 要 】

Background

Oncolytic viruses represent a novel form of cancer immunotherapy. Vaccinia viruses encoding human T cell co-stimulatory molecules have demonstrated clinical activity in phase I clinical trials in patients with advanced melanoma. However, predictive biomarkers of therapeutic response have not yet been identified.

Methods

A customized microarray was performed to identify changes in peripheral blood mononuclear cell (PBMC) gene expression upon exposure to recombinant oncolytic vaccinia viruses. Up-regulated and down-regulated genes were identified and selected for further analysis using PBMC samples from normal donors and oncolytic virus-treated patients before and after viral injection. Quantitative PCR and flow cytometry of defined T cell subsets was performed to evaluate expression patterns and clinical correlations.

Results

The microarray identified 301 genes that were up-regulated and 960 genes that were down-regulated in T cells after exposure to oncolytic vaccinia virus. The B7.1 gene was highly up-regulated and the immunoglobulin-like transcript 2 (ILT2) gene was highly down-regulated by vaccinia-B7.1, which was consistent with the known inverse regulation of these two genes. We observed an inverse association between ILT2 expression in the tumor microenvironment and clinical response and further identified ILT2 as a marker of regulatory CD4+ and suppressor CD8+ T cell responses and whose down-regulation was predictive of therapeutic responses in patients treated with oncolytic virus immunotherapy.

Conclusions

ILT2 is a new putative biomarker of T cell and clinical response in patients treated with oncolytic vaccinia virus immunotherapy. Further confirmation of ILT2 as a biomarker requires prospective validation in a larger series of clinical trials.

【 授权许可】

   
2014 Zloza et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Goldufsky J, Sivendran S, Harcharik S, Pan M, Bernardo S, Stern RH, Friedlander P, Ruby CE, Saenger Y, Kaufman HL: Oncolytic viruses for cancer treatment. Oncolytic Virotherapy 2013, 2:31-46.
• [2]Parato KA, Breitbach CJ, Le Boeuf F, Wang J, Storbeck C, Ilkow C, Diallo JS, Falls T, Burns J, Garcia V, et al.: The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther 2012, 20:749-758.
• [3]Kaufman HL, Deraffele G, Mitcham J, Moroziewicz D, Cohen SM, Hurst-Wicker KS, Cheung K, Lee DS, Divito J, Voulo M, et al.: Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. J Clin Invest 2005, 115:1903-1912.
• [4]Kaufman HL, Cohen S, Cheung K, DeRaffele G, Mitcham J, Moroziewicz D, Schlom J, Hesdorffer C: Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors. Hum Gene Ther 2006, 17:239-244.
• [5]Kaufman HL, Taback B, Sherman W, Kim DW, Shingler WH, Moroziewicz D, DeRaffele G, Mitcham J, Carroll MW, Harrop R, et al.: Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5 T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. J Transl Med 2009, 7:2. BioMed Central Full Text
• [6]Seet BT, Johnston JB, Brunetti CR, Barrett JW, Everett H, Cameron C, Sypula J, Nazarian SH, Lucas A, McFadden G: Poxviruses and immune evasion. Annu Rev Immunol 2003, 21:377-423.
• [7]Suciu-Foca N, Feirt N, Zhang QY, Vlad G, Liu Z, Lin H, Chang CC, Ho EK, Colovai AI, Kaufman H, et al.: Soluble Ig-like transcript 3 inhibits tumor allograft rejection in humanized SCID mice and T cell responses in cancer patients. J Immunol 2007, 178:7432-7441.
• [8]Chang CC, Ciubotariu R, Manavalan JS, Yuan J, Colovai AI, Piazza F, Lederman S, Colonna M, Cortesini R, Dalla-Favera R, Suciu-Foca N: Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol 2002, 3:237-243.
• [9]Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, Stoutenburg J, Cheung K, Hesdorffer C, Kim-Schulze S, Kaufman HL: Characterization of CD4 + CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 2006, 24:1169-1177.
• [10]Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G, et al.: Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009, 15:7412-7420.
• [11]Colonna M, Navarro F, Bellon T, Llano M, Garcia P, Samaridis J, Angman L, Cella M, Lopez-Botet M: A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med 1997, 186:1809-1818.
• [12]Cosman D, Fanger N, Borges L, Kubin M, Chin W, Peterson L, Hsu ML: A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity 1997, 7:273-282.
• [13]Long EO: Regulation of immune responses through inhibitory receptors. Annu Rev Immunol 1999, 17:875-904.
• [14]Veillette A, Latour S, Davidson D: Negative regulation of immunoreceptor signaling. Annu Rev Immunol 2002, 20:669-707.
• [15]Paul P, Rouas-Freiss N, Khalil-Daher I, Moreau P, Riteau B, Le Gal FA, Avril MF, Dausset J, Guillet JG, Carosella ED: HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci U S A 1998, 95:4510-4515.
• [16]Zhang W, Liang S, Wu J, Horuzsko A: Human inhibitory receptor immunoglobulin-like transcript 2 amplifies CD11b + Gr1+ myeloid-derived suppressor cells that promote long-term survival of allografts. Transplantation 2008, 86:1125-1134.
• [17]Liang S, Zhang W, Horuzsko A: Human ILT2 receptor associates with murine MHC class I molecules in vivo and impairs T cell function. Eur J Immunol 2006, 36:2457-2471.
• [18]Feger U, Tolosa E, Huang YH, Waschbisch A, Biedermann T, Melms A, Wiendl H: HLA-G expression defines a novel regulatory T-cell subset present in human peripheral blood and sites of inflammation. Blood 2007, 110:568-577.
• [19]Postow MA, Harding J, Wolchok JD: Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. Cancer J 2012, 18:153-159.
• [20]Nagorsen D, Deola S, Smith K, Wang E, Monsurro V, Zanovello P, Marincola FM, Panelli MC: Polarized monocyte response to cytokine stimulation. Genome Biol 2005, 6:R15. BioMed Central Full Text
• [21]Wang E, Miller LD, Ohnmacht GA, Liu ET, Marincola FM: High-fidelity mRNA amplification for gene profiling. Nat Biotechnol 2000, 18:457-459.